These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37176536)

  • 41. [Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder?].
    Paslakis G; Kiefer F; Diehl A; Alm B; Sobanski E
    Nervenarzt; 2010 Mar; 81(3):277-88. PubMed ID: 20108084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.
    van Emmerik-van Oortmerssen K; van de Glind G; Koeter MW; Allsop S; Auriacombe M; Barta C; Bu ET; Burren Y; Carpentier PJ; Carruthers S; Casas M; Demetrovics Z; Dom G; Faraone SV; Fatseas M; Franck J; Johnson B; Kapitány-Fövény M; Kaye S; Konstenius M; Levin FR; Moggi F; Møller M; Ramos-Quiroga JA; Schillinger A; Skutle A; Verspreet S; ; van den Brink W; Schoevers RA
    Addiction; 2014 Feb; 109(2):262-72. PubMed ID: 24118292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment.
    Benkert D; Krause KH; Wasem J; Aidelsburger P
    GMS Health Technol Assess; 2010 Sep; 6():Doc13. PubMed ID: 21289886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attention-deficit/hyperactivity disorder subtypes and substance use and use disorders in NESARC.
    De Alwis D; Lynskey MT; Reiersen AM; Agrawal A
    Addict Behav; 2014 Aug; 39(8):1278-85. PubMed ID: 24821471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of anxiety disorders in children with attention-deficit hyperactivity disorder: a narrative review.
    Golubchik P; Weizman A
    Int Clin Psychopharmacol; 2021 Jan; 36(1):1-11. PubMed ID: 33086253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management.
    Pliszka SR
    Paediatr Drugs; 2003; 5(11):741-50. PubMed ID: 14580223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
    Dalsgaard S; Mortensen PB; Frydenberg M; Thomsen PH
    Addict Behav; 2014 Jan; 39(1):325-8. PubMed ID: 24090624
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review.
    Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens A; Dalsgaard S; van den Brink W; Hendriks V
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.
    Torgersen T; Gjervan B; Rasmussen K; Vaaler A; Nordahl HM
    Atten Defic Hyperact Disord; 2013 Mar; 5(1):59-67. PubMed ID: 23104523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders.
    Skoglund C; Brandt L; D'Onofrio B; Larsson H; Franck J
    Eur Neuropsychopharmacol; 2017 Nov; 27(11):1144-1152. PubMed ID: 28935267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder.
    Khoodoruth MAS; Ouanes S; Khan YS
    Res Dev Disabil; 2022 Sep; 128():104275. PubMed ID: 35691145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Adolescents with concurrent ADHD and substance use disorder; international consensus].
    Spijkerman R; Crunelle CL; Özgen MH; Begeman AHA; Dom G; van de Glind G; Groenman AP; van Kernebeek MW; Matthys F; Post M; Schellekens A; Staal W; van den Brink W; Hendriks VM
    Tijdschr Psychiatr; 2021; 63(12):868-874. PubMed ID: 34978058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities.
    Van de Glind G; Brynte C; Skutle A; Kaye S; Konstenius M; Levin F; Mathys F; Demetrovics Z; Moggi F; Ramos-Quiroga JA; Schellekens A; Crunelle C; Dom G; van den Brink W; Franck J
    Eur Addict Res; 2020; 26(4-5):173-178. PubMed ID: 32599579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of ADHD and its treatment on substance abuse in adults.
    Wilens TE
    J Clin Psychiatry; 2004; 65 Suppl 3():38-45. PubMed ID: 15046534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Onset and Severity of Early Disruptive Behavioral Disorders in Treatment-Seeking Substance Use Disorder Patients with and without Attention-Deficit/Hyperactivity Disorder.
    González RA; Vélez-Pastrana MC; Blankers M; Bäcker A; Konstenius M; Holtmann M; Levin FR; Noack M; Kaye S; Demetrovics Z; van de Glind G; van den Brink W; Schellekens A;
    Eur Addict Res; 2020; 26(4-5):211-222. PubMed ID: 32594079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Attention Deficit Hyperactivity Disorder Increases Nicotine Addiction Severity in Adults Seeking Treatment for Substance Use Disorders: The Role of Personality Disorders.
    Sánchez-García NC; González RA; Ramos-Quiroga JA; van den Brink W; Luderer M; Blankers M; Grau-Lopez L; Levin FR; Kaye S; Demetrovics Z; van de Glind G; Schellekens A; Vélez-Pastrana MC;
    Eur Addict Res; 2020; 26(4-5):191-200. PubMed ID: 32564016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.
    Szobot CM; Shih MC; Schaefer T; Júnior N; Hoexter MQ; Fu YK; Pechansky F; Bressan RA; Rohde LA
    Neuroimage; 2008 Apr; 40(3):1195-201. PubMed ID: 18282769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of substance misuse and current family history of substance use disorder on brain structure in adolescents and young adults with attention-deficit/hyperactivity disorder.
    Novi M; Paraskevopoulou M; Van Rooij D; Schene AH; Buitelaar JK; Schellekens AFA
    Drug Alcohol Depend; 2021 Nov; 228():109032. PubMed ID: 34555690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ADHD stimulant medication misuse and considerations for current prescribing practice: a literature review.
    Carolan D
    Ir J Med Sci; 2022 Feb; 191(1):313-320. PubMed ID: 33559870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills.
    Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
    BMC Psychiatry; 2013 Dec; 13():336. PubMed ID: 24330331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.